Annexin II: A mediator of the plasmin/plasminogen activator system

Trends in Cardiovascular Medicine

Volumn 9, Issue 5, 1999, Pages 128-138

  Hajjar, Katherine A ^a   Krishnan, Suba ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANNEXIN; HOMOCYSTEINE; LIPOPROTEIN A; PLASMIN; PLASMINOGEN ACTIVATOR; TISSUE PLASMINOGEN ACTIVATOR;

BLOOD CLOT LYSIS; COMPLEX FORMATION; FIBRINOLYSIS; HUMAN; MEMBRANE BINDING; NONHUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW;

AMINO ACID SEQUENCE; ANIMALS; ANNEXIN A2; ENDOTHELIUM, VASCULAR; FIBRINOLYSIS; HUMANS; MOLECULAR SEQUENCE DATA; PLASMIN; PLASMINOGEN; RECEPTORS, CELL SURFACE; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0033407492     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1050-1738(99)00020-1     Document Type: Review

References (107)

1. Ali S.M., Geisow M.J., Burgoyne R.D. A role for calpactin in calcium-dependent exocytosis in adrenal chromaffin cells. Nature. 340:1989;313-315.
2. Bauer P.I., Machovich R., Buki K.G.et al. Interaction of plasmin with endothelial cells. Biochem J. 218:1984;119-124.
3. Benz J., Hofmann A. Annexins. from structure to function Biol Chem. 378:1997;177-183.
4. Bold S., Ohlin M., Garten W.et al. Structural domains involved in human cytomegalovirus glycoprotein B-mediated cell-cell fusion. J Gen Virol. 77:1996;2297-2302.
5. Boonmark N.W., Lou X.J., Schwartz K.et al. Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice. J Clin Invest. 100:1997;558-564.
6. Boushey C.J., Beresford S.A.A., Omenn G.S.et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA. 274:1995;1049-1057.
7. Brambilla R., Zippel R., Sturani E.et al. Characterization of the tyrosine phosphorylation of calpactin I (annexin II) induced by platelet-derived growth factor. Biochem J. 278:1991;447-452.
8. Burger A., Berendes R., Liemann S.et al. The crystal structure and ion channel activity of human annexin II, a peripheral membrane protein. J Mol Biol. 257:1996;839-847.
9. Burgoyne R.D., Cambray-Deakin M.A., Norman K.M. Developmental regulation of tyrosine kinase substrate p36 (calpactin heavy chain) in rat cerebellum. J Mol Neurosci. 1:1989;47-54.
10. Carter C.V., Howlett A.R., Martin G.S.et al. The tyrosine phosphorylation substrate p36 is developmentally regulated in embryonic avian limb and is induced in cell culture. J Cell Biol. 103:1986;2017-2024.
11. Cesarman G.M., Guevara C.A., Hajjar K.A. An endothelial cell receptor for plasminogen/tissue plasminogen activator. II. Annexin II-mediated enhancement of tPA-dependent plasminogen activation J Biol Chem. 269:1994;21198-21203.
12. Choi K.S., Ghuman J., Kassam G.et al. Annexin II tetramer inhibits plasmin-dependent fibrinolysis. Biochemistry. 37:1998;648-655.
13. Chung C.Y., Erickson H.P. Cell surface annexin II is a high affinity receptor for the alternatively spliced segment of tenascin-C. J Cell Biol. 126:1994;539-548.
14. Chung C.Y., Murphy-Ullrich J.E., Erickson H.P. Mitogenesis, cell migration and loss of focal adhesion induced by tenascin-C interacting with its cell surface receptor, annexin II. Mol Biol Cell. 7:1996;883-892.
15. Clark G.B., Roux S.J. Annexins in plant cells. Plant Physiol. 109:1995;1133-1139.
16. ++-induced conformational changes Science. 261:1993;1321-1324.
17. Creutz C.E. The annexins and exocytosis. Science. 258:1992;924-931.
18. +-binding protein p68 a novel member of a protein family. EMBO J. 7:1988;21-27. [published erratum appears in EMBO J 1988;7:1914].
19. Emans N., Gorvel J.P., Walter C.et al. Annexin II is a major component of fusogenic endosomal vesicles. J Cell Biol. 120:1993;1357-1369.
20. Erikson E., Erikson R.L. Identification of a cellular protein substrate phosphorylated by the avian sarcoma virus-transforming gene product. Cell. 21:1980;829-836.
21. Favier-Perron B., Lewit-Bentley A., Russo-Marie F. The high-resolution crystal structure of human annexin III shows subtle differences with annexin V. Biochemistry. 35:1996;1740-1744.
22. Fey M.F., Moffat G.J., Vik D.P.et al. Complete structure of the murine p36 (annexin II) gene. Identification of mRNAs for both the murine and the human gene with alternatively spliced. 5′(ncoding exons. Biochim Biophys Acta 1306):1996;160-170.
23. Frosst P., Blom H.J., Milos R.et al. A candidate genetic risk factor for vascular disease. a common mutation in methylenetetrahydrofolate reductase Nat Genet. 10:1995;111-113.
24. Gerke V: 1992. Evolutionary conservation and three-dimensional folding of the tyrosine kinase substrate annexin II. In Moss SE, ed. The Annexins. London, Portland Press, pp. 47-59.
25. Gerke V., Weber K. Calcium-dependent conformational changes in the 36-kDa subunit of intestinal protein I related to the cellular 36-kDa target of Rous sarcoma virus tyrosine kinase. J Biol Chem. 260:1985;1688-1695.
26. ++ binding by the 36-kDa tyrosine kinase substrate (calpactin) and its 33-kDa core. J Biol Chem. 261:1986;7247-7252.
27. Glenney J.R., Boudreau M., Galyean R.et al. Association of the S-100-related calpactin I light chain with the NH2-terminal tail of the 36-kDa heavy chain. J Biol Chem. 261:1986;10,485-10,488.
28. Gonzales-Gronow M., Edelberg J.M., Pizzo S.V. Further characterization of the cellular plasminogen binding site. evidence that plasminogen 2 and lipoprotein a compete for the same site Biochemistry. 28:1989;2374-2377.
29. Gould K.L., Cooper J.A., Hunter T. The 46,000-dalton tyrosine kinase substrate is widespread, whereas the 36,000-dalton substrate is only expressed at high levels in certain rodent tissues. J Cell Biol. 98:1984;487-497.
30. Gould K.L., Woodgett J.R., Isacke C.M.et al. The protein-tyrosine kinase substrate p36 is also a substrate for protein kinase C in vitro and in vivo. Mol Cell Biol. 6:1986;2738-2744.
31. Goulet F., Moore K.G., Sartorelli A.C. Glycosylation of annexin I and annexin II. Biochem Biophys Res Commun. 188:1992;554-558.
32. Graham I.M., Daly L.E., Refsum H.M.et al. Plasma homocysteine as a risk factor for vascular disease. the European Concerted Action Project JAMA. 277:1997;1775-1781.
33. Grainger D.J., Kemp P.R., Liu A.C.et al. Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice. Nature. 370:1994;460-462.
34. Greenberg M.E., Brackenbury R., Edelman G.M. Changes in the distribution of the 34-kdalton tyrosine kinase substrate during differentiation and maturation of chicken tissues. J Cell Biol. 98:1984;473-486.
35. Hajjar K.A. The endothelial cell tissue plasminogen activator receptor. specific interaction with plasminogen J Biol Chem. 266:1991;21,962-21,970.
36. Hajjar K.A. Homocysteine-induced modulation of tissue plasminogen activator to its endothelial cell membrane receptor. J Clin Invest. 91:1993;2873-2879.
37. Hajjar KA: 1998. The molecular basis of fibrinolysis. In Nathan DG, Orkin SH, eds. Hematology of Infancy and Childhood. Philadelphia: WB Saunders, pp. 1557-1573.
38. Hajjar K.A., Hamel N.M. Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase. J Biol Chem. 265:1990;2908-2916.
39. Hajjar K.A., Jacovina A.T. Modulation of annexin II by homocysteine. implications for atherothrombosis J Invest Med. 46:1998;1-6.
40. Hajjar K.A., Nachman R.L. Endothelial cell-mediated conversion of glu-plasminogen to lys-plasminogen. further evidence for assembly of the fibrinolytic system on the endothelial cell surface J Clin Invest. 82:1988;1769-1778.
41. Hajjar K.A., Nachman R.L. The role of lipoprotein(a) in atherogenesis and thrombosis. Ann Rev Med. 47:1996;423-442.
42. Hajjar K.A., Harpel P.C., Jaffe E.A.et al. Binding of plasminogen to cultured human endothelial cells. J Biol Chem. 261:1986;11,656-11,662.
43. Hajjar K.A., Hamel N.M., Harpel P.C.et al. Binding of tissue plasminogen activator to cultured human endothelial cells. J Clin Invest. 80:1987;1712-1719.
44. Hajjar K.A., Gavish D., Breslow J.et al. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature. 339:1989;303-305.
45. Hajjar K.A., Jacovina A.T., Chacko J. An endothelial cell receptor for plasminogen and tissue plasminogen activator. I. Identity with annexin II J Biol Chem. 269:1994;21,191-21,197.
46. Hajjar K.A., Guevara C.A., Lev E.et al. Interaction of the fibrinolytic receptor, annexin II, with the endothelial cell surface. essential role of endonexin repeat 2 J Biol Chem. 271:1996;21,652-21,659.
47. Hajjar K.A., Mauri L., Jacovina A.T.et al. Tissue plasminogen activator binding to the annexin II tail domain. direct modulation by homocysteine J Biol Chem. 273:1998;9987-9993.
48. Hamre K.M., Chepenik K.P., Goldowitz D. The annexins. specific markers of midline structures and sensory neurons in the developing murine central nervous system J Comp Neurol. 352:1995;421-435.
49. Hamre K.M., Keller-Peck C.R., Campbell R.M.et al. Annexin IV is a marker of roof and floor plate development in the murine CNS. J Comp Neurol. 368:1996;527-537.
50. Huang K., Wallner B.P., Mattaliano R.J.et al. Two human 35 kd inhibitors of phospholipase A2 are related to substrates of pp60 v-src and of the epidermal growth factor receptor/kinase. Cell. 46:1986;191-199.
51. Huber R., Berendes R., Burger A.et al. Crystal and molecular structure of human annexin V after refinement. implications for structure, membrane binding and ion channel formation of the annexin family of proteins J Mol Biol. 223:1992;683-704.
52. Huebner K., Cannizzaro L.A., Frey A.Z.et al. Chromosomal localization of the genes for lipocortin I and lipocortin II. Oncogene Res. 2:1988;299-310.
53. Isacke C.M., Trowbridge I.S., Hunter T. Modulation of p36 phosphorylation in human cells. studies using anti-p36 monoclonal antibodies Mol Cell Biol. 6:1986;2745-2751.
54. Izant J.G., Bryson L.J. Xenopus annexin II (calpactin II) heavy chain has a distinct amino terminus. J Biol Chem. 266:1991;18,560-18,566.
55. Jindahl H.K., Chaney W.G., Anderson C.W.et al. The protein-tyrosine kinase substrate, calpactin I heavy chain (p36), is part of the primer recognition protein complex that interacts with DNA polymerase α J Biol Chem. 266:1991;5169-5176.
56. Johnsson N., Marriott G., Weber K. p36, the major cytoplasmic substrate of src tyrosine protein kinase, binds to its p11 regulatory subunit via a short amino-terminal amphipathic helix. EMBO J. 7:1988;2435-2442.
57. ++-binding sites in human annexin II. Eur J Biochem. 207:1992;923-930.
58. ++-binding sites. Biochem J. 298:1994;553-559.
59. Kaetzel M.A., Dedman J.R. Annexins. novel calcium-dependent regulators of membrane function News in Physiol Sci. 10:1995;171-176.
60. Karasik A., Pepinsky R.B., Shoelson S.E.et al. Lipocortins 1 and 2 as substrates for the insulin receptor kinase in rat liver. J Biol Chem. 263:1988;11,862-11,867.
61. Kassam G., Choi K.S., Ghuman J.et al. The role of annexin II tetramer in the activation of plasminogen. J Biol Chem. 273:1998;4790-4799. a.
62. Kassam G., Le B.H., Choi K.S.et al. The p11 subunit of the annexin II tetramer plays a key role in the stimulation of tPA-dependent plasminogen activation. Biochemistry. 37:1998;16,958-16,966. b.
63. Kraus J.P. Molecular basis of phenotype expression in homocystinuria. J Inherit Metab Dis. 17:1994;383-390.
64. Kristoffersen E.K., Matre R. Surface annexin II on placental membranes of the fetomaternal interface. Am J Reprod Immunol. 36:1996;141-149.
65. Lawn R.M., Wade D.P., Hammer R.E.et al. Atherogenesis in transgenic mice expressing human apolipoprotein(a). Nature. 360:1992;670-672.
66. Le Cabec V., Russo-Marie F., Maridonneau-Parini I. Differential expression of two forms of annexin 3 in human neutrophils and monocytes and along their differentiation. Biochem Biophys Res Commun. 189:1992;1471-1476.
67. Liemann S., Lewit-Bentley A. Annexins. a novel family of calcium- and membrane-binding proteins in search of a function Structure. 3:1995;233-237.
68. Loscalzo J. Lipoprotein(a), a unique risk factor for atherothrombotic disease. Arteriosclerosis. 10:1990;672-679.
69. Lozano J.J., Silberstein G.B., Hwang S.I.et al. Developmental regulation of calcium-binding proteins (calelectrins and calpactin I) in mammary glands. J Cell Physiol. 138:1989;503-510.
70. Luecke H., Chang B.T., Mailliard W.S.et al. Crystal structure of the annexin XII hexamer and implications for bilayer insertion. Nature. 378:1995;512-515.
71. Magendzo K., Shirvan A., Cultraro C.et al. Alternative splicing of human synexin mRNA in brain, cardiac, and skeletal muscle alters the unique N-terminal domain. J Biol Chem. 266:1991;3228-3232.
72. McKanna J.A., Cohen S. The EGF receptor kinase substrate p35 in the floor plate of the embryonic rat CNS. Science. 243:1989;1477-1479.
73. McLean J.W., Tomlinson J.E., Kuang W.J.et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 330:1987;132-137.
74. Menell J.S., Cesarman G.M., Jacovina A.T.et al. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med. 340:1999;994-1004.
75. Miles L.A., Fless G.M., Levin E.G.et al. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature. 339:1989;301-303.
76. +-binding protein. FEBS Lett. 261:1990;299-302.
77. Moss S.E. Annexins taken to task. Nature. 378:1995;446-447.
78. Moss S.E. Annexins. Trends Cell Biol. 7:1997;87-89.
79. Mudd H., Skovby F., Levy H.L.et al. The natural history of homocystinuria due to cystathionine b-synthase deficiency. Am J Hum Genet. 37:1985;1-31.
80. Mudd H, Levy HL, Skovby F, et al.: 1995. Disorders of transsulfuration. In Scriver CR, Beaudet AL, Sly WS, et al., eds. The Metabolic and Molecular Basis of Inherited Disease. New York, McGraw-Hill, pp. 1279-1327.
81. Newman R., Tucker A., Ferguson C.et al. Crystallization of p68 on lipid monolayers and as three-dimensional single crystals. J Mol Biol. 206:1989;213-219.
82. Nygard O., Nordrehaug J.E., Refsum H.et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 337:1997;230-236.
83. Palabrica T.M., Liu A.C., Aronovitz M.J.et al. Antifibrinolytic activity of apolipoprotein(a) in vivo. human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis Nature Med. 1:1995;256-259.
84. Radke K., Gilmore T., Martin G.S. Transformation by Rous sarcoma virus. a cellular substrate for transformation-specific protein phosphorylation contains phosphotyrosine Cell. 21:1980;821-828.
85. Raynal P., Pollard H.B. Annexins. the problem of assessing the biologic role for a gene family of multifunctional calcium- and phospholipid-binding proeins Biochim Biophys Acta. 1197:1994;63-93.
86. Reeves S.A., Chavez-Kappel C., Davis R.et al. Developmental regulation of annexin II (lipocortin 2) in human brain and expression in high grade glioma. Cancer Res. 52:1992;6871-6876.
87. Refsum H., Ueland P.M., Nygard O.et al. Homocysteine and cardiovascular disease. Ann Rev Med. 49:1998;31-62.
88. Roth D., Morgan A., Burgoyne R.D. Identification of a key domain in annexin and 14-3-3 proteins that stimulate calcium-dependent exocytosis in permeabilized adrenal chromaffin cells. FEBS Lett. 320:1993;207-210.
89. Scanu A.M., Fless G.M. Lipoprotein(a) heterogeneity and biologic relevance. J Clin Invest. 85:1990;1709-1715.
90. Selhub J., Jacques P.F., Bostom A.G.et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med. 332:1995;286-291.
91. Siever D.A., Erickson H.P. Extracellular annexin II. Int J Biochem Cell Biol. 29:1997;1219-1223.
92. Spano F., Raugei G., Palla E.et al. Characterization of the human lipocortin-2-encoding multigene family. its structure suggests the existence of a short amino acid unit undergoing duplication Gene. 95:1990;243-251.
93. Stahl A., Mueller B.M. The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in caveolae. J Cell Biol. 129:1995;335-344.
94. Summers T.A., Creutz C.E. Phosphorylation of a chromaffin granule-binding protein by protein kinase C. J Biol Chem. 260:1985;2437-2443.
95. Swairjo M.A., Seaton B.A. Annexin structure and membrane interactions. a molecular perspective Ann Rev Biophys Biomol Struct. 23:1994;193-213.
96. Towle C.A., Weissbach L., Treadwell B.V. Alternatively spliced annexin XI transcripts encode proteins that differ near the amino terminus. Biochim Biophys Aca. 1131:1992;223-226.
97. Tressler R.J., Nicolson G.L. Butanol-extractable and detergent-solubilized cell surface components from murine large cell lymphoma cells associated with adhesion to organ microvessel endothelial cells. J Cell Biochem. 48:1992;162-171.
98. Tressler R.J., Updyke T.V., Yeatman T.J.et al. Extracellular annexin is associated with divalent cation-dependent tumor cell adhesion of metastatic RAW 117 large-cell lymphoma cells. J Cell Biochem. 53:1993;265-276.
99. Utermann G. The mysteries of lipoprotein(a). Science. 246:1989;904-910.
100. Waisman D.M. Annexin II tetramer. structure and function Mol Bell Biochem. 149(150):1995;301-322.
101. Weitkamp L.R., Guttormsen S.A., Schultz J.S. Linkage between the loci for the Lp(a) lipoprotein (Lp) and plasminogen (PLG). Hum Genet. 79:1988;80-82.
102. Weng X., Luecke H., Song I.S.et al. Crystal structure of human annexin I at 2.5A resolution. Protein Sci. 2:1993;448-458.
103. Wright J.F., Kurosky A., Wasi S. An endothelial cell-surface form of annexin II binds human cytomegalovirus. Biochem Biophys Res Commun. 198:1994;983-989.
104. Wright J.F., Kurosky A., Pryzdial E.L.G.et al. Host cellular annexin II is associated with cytomegalovirus particles isolated from cultured human fibroblasts. J Virol. 69:1995;4784-4791.
105. Yeatman T.J., Updyke T.V., Kaetzel M.A.et al. Expression of annexins on the surfaces of non-metastatic human and rodent tumor cells. Clin Exp Metastasis. 11:1993;37-44.
106. Zanotti G., Malpeli G., Gliubich F.et al. Structure of the trigonal crystal form of bovine annexin IV. Biochem J. 329:1998;101-106.
107. Zhang-Keck Z.Y., Burns A.L., Pollard H.B. Genomic organization and chromosomal localization of the mouse synexin gene. Biochem J. 289:1993;735-741.